Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Cash from Investing Activities (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Cash from Investing Activities for 6 consecutive years, with $4.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 91.01% to $4.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $113.0 million, a 834.95% increase, with the full-year FY2025 number at $113.0 million, up 834.95% from a year prior.
  • Cash from Investing Activities was $4.8 million for Q4 2025 at Lexicon Pharmaceuticals, down from $52.1 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $53.7 million in Q4 2024 to a low of -$110.2 million in Q1 2024.
  • A 3-year average of $4.0 million and a median of $13.8 million in 2023 define the central range for Cash from Investing Activities.
  • Biggest YoY gain for Cash from Investing Activities was 235.96% in 2024; the steepest drop was 1011.47% in 2024.
  • Lexicon Pharmaceuticals' Cash from Investing Activities stood at $51.9 million in 2023, then rose by 3.47% to $53.7 million in 2024, then crashed by 91.01% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Cash from Investing Activities are $4.8 million (Q4 2025), $52.1 million (Q3 2025), and $15.5 million (Q2 2025).